June 17 (Reuters) - AstraZeneca's blockbuster cancer drug Imfinzi combined with chemotherapy has been approved in the U.S. as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient, the drugmaker said. (Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)